Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORIC Oric Pharmaceuticals	$9.24 -4.0%	$10.23	$3.90 ▼ $14.67	$820.71M	1.69	1.21 million shs	1.05 million shs
PRQR ProQR Therapeutics	$2.17 +5.9%	$2.09	$1.07 ▼ $4.62	$215.69M	0.43	210,915 shs	312,555 shs
SNDX Syndax Pharmaceuticals	$12.48 -1.9%	$10.08	$8.58 ▼ $22.50	$1.10B	0.74	2.42 million shs	2.85 million shs
TRVI Trevi Therapeutics	$7.42 +1.6%	$6.58	$2.36 ▼ $8.11	$856.24M	0.58	1.79 million shs	1.95 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORIC Oric Pharmaceuticals	-4.05%	-8.70%	-15.23%	+81.89%	+9.09%
PRQR ProQR Therapeutics	+5.85%	+4.33%	-5.65%	+34.78%	+18.58%
SNDX Syndax Pharmaceuticals	-1.89%	+25.05%	+35.06%	+16.64%	-36.07%
TRVI Trevi Therapeutics	+1.64%	+1.23%	+20.26%	+12.42%	+186.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ORIC Oric Pharmaceuticals	4.2278 of 5 stars	3.5	1.0	4.4	3.1	3.3	0.6
PRQR ProQR Therapeutics	2.4989 of 5 stars	4.6	3.0	0.0	1.4	0.0	0.0
SNDX Syndax Pharmaceuticals	4.2109 of 5 stars	4.5	1.0	4.4	3.8	0.8	0.0
TRVI Trevi Therapeutics	3.0071 of 5 stars	4.7	1.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	100.99% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	268.66% Upside
SNDX Syndax Pharmaceuticals	3.00	Buy	$36.91	195.75% Upside
TRVI Trevi Therapeutics	3.30	Buy	$20.38	174.60% Upside

Current Analyst Ratings Breakdown

Latest PRQR, ORIC, TRVI, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
8/6/2025	SNDX Syndax Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	SNDX Syndax Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$46.00 ➝ $51.00
8/5/2025	SNDX Syndax Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$43.00 ➝ $56.00
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.16	N/A	N/A	$0.91 per share	2.38
SNDX Syndax Pharmaceuticals	$23.68M	45.40	N/A	N/A	$1.83 per share	6.82
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/14/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.89	N/A	N/A	N/A	-428.48%	-130.47%	-56.12%	N/A
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-54.98%	-49.47%	N/A

Latest PRQR, ORIC, TRVI, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
PRQR ProQR Therapeutics	N/A	4.10	4.10
SNDX Syndax Pharmaceuticals	2.06	4.71	5.75
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ORIC Oric Pharmaceuticals	95.05%
PRQR ProQR Therapeutics	32.65%
SNDX Syndax Pharmaceuticals	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ORIC Oric Pharmaceuticals	6.82%
PRQR ProQR Therapeutics	8.40%
SNDX Syndax Pharmaceuticals	4.10%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.14 million	82.61 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

PRQR, ORIC, TRVI, and SNDX Headlines

Recent News About These Companies

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00

August 9 at 8:56 AM | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

August 8 at 2:10 PM | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7 at 4:18 PM | prnewswire.com

41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbH

August 4, 2025 | marketbeat.com

Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 6,352.7%

August 3, 2025 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 6,352.7% in July

August 2, 2025 | marketbeat.com

Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Thursday

August 2, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 0.1% - Here's What Happened

August 1, 2025 | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

July 31, 2025 | prnewswire.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 29, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Time to Buy?

July 24, 2025 | marketbeat.com

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

July 11, 2025 | zacks.com

Trevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

July 2, 2025 | msn.com

TRVI Trevi Therapeutics, Inc. - Seeking Alpha

July 1, 2025 | seekingalpha.com

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

July 1, 2025 | prnewswire.com

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm

June 26, 2025 | globenewswire.com

TRVI - Trevi Therapeutics Inc Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
By Thomas Hughes | July 19, 2025
View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
Vertical Aerospace Stock Trades at Discount After VX4 Milestone
By Jeffrey Neal Johnson | July 22, 2025
View Vertical Aerospace Stock Trades at Discount After VX4 Milestone
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom

PRQR, ORIC, TRVI, and SNDX Company Descriptions

Oric Pharmaceuticals NASDAQ:ORIC

$9.24 -0.39 (-4.05%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$9.16 -0.08 (-0.81%)

As of 08/8/2025 07:46 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ProQR Therapeutics NASDAQ:PRQR

$2.17 +0.12 (+5.85%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.13 -0.04 (-1.80%)

As of 08/8/2025 04:28 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Syndax Pharmaceuticals NASDAQ:SNDX

$12.48 -0.24 (-1.89%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$12.60 +0.12 (+0.99%)

As of 08/8/2025 07:57 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Trevi Therapeutics NASDAQ:TRVI

$7.42 +0.12 (+1.64%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.42 0.00 (0.00%)

As of 08/8/2025 07:52 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time